Cisen Pharmaceutical Co Ltd

Cisen Pharmaceutical announced that its subsidiary Shandong Cisen Fodu Pharmaceutical has received the Drug Registration Certificate for loteprednol etabonate and tobramycin ophthalmic suspension issued by the National Medical Products Administration, marking the first generic approval in China. The product specification is 5 ml containing 25 mg loteprednol etabonate and 15 mg tobramycin, registered as a Category 4 chemical drug, mainly indicated for steroid-responsive inflammatory ocular conditions and associated or potential bacterial infections of the ocular surface. Cisen Pharmaceutical stated that this approval further supplements the company's product portfolio and enriches its product line, and is expected to play a positive role in the company's future development. The company also cautioned that drug launch requires a certain market development period, and product sales are subject to uncertainties from changes in pharmaceutical industry policies, bidding and procurement, market conditions, and centralized procurement, so investors should be aware of the risks.

Cisen Pharmaceutical disclosed its semi-annual report for 2026, with net profit attributable to the parent company reaching 264 million yuan in the first half, up 15.40% year on year. Total operating revenue for the same period was 1.693 billion yuan, down 2.68% year on year. Net profit excluding non-recurring items was 158 million yuan, down 12.00% year on year. Net cash flow from operating activities was 427 million yuan, up 20.88% year on year. The company plans to distribute a cash dividend of 2.16 yuan per 10 shares, tax included, to all shareholders.

Cisen Pharmaceutical released its 2026 half-year report. Net profit attributable to the parent in the first half was 264 million yuan, up 15.4% year on year. Operating revenue was 1.69 billion yuan, down 2.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 158 million yuan, down 12.0% year on year. Net operating cash flow was 427 million yuan, up 20.9% year on year. Second-quarter net profit attributable to the parent was 134 million yuan, up 56.2% year on year. The company said overall operations were stable, with its main business still concentrated in the pharmaceutical manufacturing industry.

Cisen Pharmaceutical announced plans to distribute a cash dividend of 0.216 yuan per share, before tax, to all shareholders, with an estimated total payout of 97.79 million yuan, representing 36.98% of half-year net profit attributable to the parent company. In the first half of 2026, the company achieved revenue of 1.693 billion yuan and net profit attributable to the parent company of 264 million yuan.